PreciseDx Announces Formation of Scientific Advisory Board
recent articles
CHICAGO--(BUSINESS WIRE)--Nucleai, a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, today announced a strategic collaboration...
Indica Labs and Molecular Instruments Announce Partnership to Advance AI-Powered Quantitative Image Analysis with HCR™ RNA-ISH Albuquerque, NM, and Los Angeles, CA 5 April 2024 — Indica Labs, a leading provider of AI-powered...
The Extension Funds Nucleai to Advance Its First-in-Class Spatial AI Biomarker in Active Clinical Enrollment Investment Expands Deployments of AI-Powered Spatial Biomarker Technology, Strengthening Companion Diagnostics for ADCs,...
From the Lumea Podcast - Ask A Pathologist: Welcome to our seventh episode of the Ask a Pathologist Podcast, Innovators in Action. We had the privilege to interview Dr. Todd Randolph about artificial intelligence and its current and future...
PreciseDx: Sponsored collaboration will focus on evaluating the ability of PreciseBreast™ to accurately predict breast cancer recurrence for those patients with TNBC NEW YORK, April 2, 2024 /PRNewswire/ -- PreciseDx®, a leading...
Deep Bio: Three posters will be presented at the AACR Annual Meeting 2024 to spotlight Deep Bio's pioneering research and advancements in AI within digital pathology SEOUL, SOUTH KOREA, March 28, 2024 /EINPresswire.com/ -- Deep Bio, a...
